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ABSTRACT
Pertussis vaccination of parents and household contacts (‘cocooning’) to protect newborn infants is
an established strategy in many countries, although uptake may be low. Many aspects may influence
such decision-making. We conducted a cross-sectional survey (NCT01890447) of households and
other close contacts of newborns aged ≤6 months (or of expectant mothers in their last trimester) in
Spain and Italy, using an adaptive discrete-choice experiment questionnaire. Aims were to assess the
relative importance of attributes influencing vaccine adoption, and to estimate variation in vaccine
adoption rates and the impact of cost on vaccination rates. Six hundred and fifteen participants
(Spain, n = 313; Italy, n = 302) completed the survey. Of 144 available questionnaire scenarios, the
most frequently selected (14% of respondents in both countries) were infant protection by house-
hold vaccination at vaccination center, recommendation by family physician and health authorities,
with information available on leaflets and websites. The attribute with highest median relative
importance was ‘reduction in source of infection’ in Spain (23.1%) and ‘vaccination location’ in
Italy (18.8%). Differences between other attributes were low in both countries, with media attributes
showing low importance. Over 80% of respondents indicated a definite or probable response to
vaccine adoption (at no-cost) with estimated probability of adoption of 89–98%; applying vaccine
costs (25€ per person) would reduce the probability of uptake by 7–20% in definite/probable
respondents. Awareness of these determinants is helpful in informing Health Authorities and
healthcare practitioners implementing a cocooning strategy for those populations where maternal
immunization is not a preferred option.
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Introduction
Although effective vaccines against pertussis disease (caused by
Bordetella pertussis) are available, with widespread implementa-
tion in childhood immunization programs, the incidence of this
disease has increased in recent years.1,2 Epidemiological studies
report a shift in the relative incidence from school-age children
to adolescents and adults including older adults, in whom per-
tussis immunity (natural or vaccine-induced) has waned, and
towards newborns and unvaccinated younger infants, in whom
pertussis morbidity and mortality is greatest.2-4
Pertussis induces substantial direct medical costs among
European countries.5–7 In Catalonia (Spain), total direct
healthcare costs in children with pertussis aged 0–9 years in
2012–13 exceeded 700,000€5 while in Portugal, total costs for
pertussis hospitalizations were higher than 2,500,000€ from
2000 to 2015.6
Maternal immunization is the most effective strategy to
reduce the risk of pertussis in newborns.2,8 Nevertheless,
alternative strategies are important when maternal immuniza-
tion is declined. Protection of unvaccinated newborns via
cocooning, where parents and other household contacts at
risk of infection are vaccinated so forming a shield against
newborn infection is an important strategy, especially in the
absence of maternal immunization or as an additional com-
plementary approach when disease prevalence is high.8-11
Cocooning has been recommended in the United States since
2006 while in Europe, cocooning has been recommended in
a number of countries (e.g., France, Switzerland, and
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Germany) and may also be recommended following acute per-
tussis outbreaks (e.g., in Australia).8,12-17 However, implementa-
tion is highly variable and vaccine uptake by parents and other
close contacts of newborns is often incomplete. For example, in
France, although parental immunization (especially in mothers)
has increased in recent years since the implementation of
a national policy in 2004, a recent study reported that immuni-
zation of both parents was found in only 26% of families with
infants aged <12 months.13 Data from Switzerland indicates that
in the years immediately following implementation of cocooning
in 2011, only 23% of mothers and 17% of fathers of newborns
were vaccinated, and vaccination of all close-contacts was seen in
only 7% of households with newborns.15
A range of determinants (or attributes) that influence vaccine
uptake/acceptance by parents and household contacts have been
reported, including risk of transmission to an infant, vaccine
access and cost, healthcare professional (HCP) recommenda-
tions and disease awareness.18-23 Key determinants may vary in
different countries and in different target groups (e.g., mother
and partner), and understanding these aspects are important in
developing and implementing a successful cocooning strategy.
In Spain, pertussis maternal immunization is well implemen-
ted in all regions (Catalonia was the first region to implement it
in January 2014) with uptake around 80%24 while in Italy,
maternal immunization is also recommended (and free of
charge). In both countries, cocooning has been proposed as an
adjunctive preventive strategy.25-27 To inform policy and deter-
mine which attributes of a pertussis cocooning vaccination
strategy are important in parental decision making, we con-
ducted a cross-sectional web-based survey in both countries,
using an adaptive discrete-choice experiment (ADCE) question-
naire (also called an adaptive choice-based conjoint [ACBC]
analysis) to measure preferences among households and other
close contacts of newborns aged ≤6 months of age and among
expectant mothers in their last trimester or their partners.
Discrete-choice experiments (DCE) are increasingly used
to evaluate individuals’ vaccination preferences and under-
lying decision-making.28-32 While DCE allows participants to
choose from a pre-defined set of attributes, an ADCE format
allows more individualized choices, with successive choice
scenarios adapted to previous questions in an interactive
manner. In this ADCE approach, the respondent is first
asked to identify their most ideal vaccination scenario, based
upon key determinants that may influence choice (source of
infection and likelihood of infection to the newborn, duration
of protection, cost, vaccination location, recommendation by
doctors or health authorities and supporting information and
other opinions). For each respondent, the relative importance
of each attribute is measured and ranked, and their personal
preferences for specific attributes valued.
For the present study, the questionnaire was designed to
minimize interaction between attributes i.e., to reduce the like-
lihood that preference for one attribute (or attribute level)
affects the relative preference of another. This was achieved
using the Sawtooth Software which uses a multinomial logit
model and hierarchical Bayesian analysis when calculating
part-worth utilities for each attribute and levels. Therefore,
the survey questionnaire shows orthogonality between attri-
butes (i.e., minimal correlation or interaction between
attributes) and minimal overlap with level balance (i.e., each
attribute appears only once in a choice set and attribute levels
occur at an equal frequency within the questionnaire). In
addition, the presence of any relevant co-linearity between
model parameters was ruled-out following visual inspection
of a scatter matrix presenting dependences between Monte-
Carlo samplings of the joint posterior distribution of the para-
meters (Supplementary Figure 1).
The primary objective was to assess the relative importance
of attributes that influence decision making in adopting per-
tussis vaccination by close contacts, with preferences evalu-
ated within each country. Additional objectives included
estimation of variations in pertussis vaccination adoption
rates by contacts, the impact of vaccine costs on adoption
rates, and to evaluate the role of demographic factors (e.g.,
gender, age) in choices and rates.
Results
Survey participants
Following a pilot questionnaire (scoped and developed based on
focus group feedback), as described in the Methods section
below, between January 2015 and February 2016 a total of 615
respondents completed the final questionnaire; 313 from Spain
and 302 from Italy. Demographic characteristics of participants
are shown in Table 1. Mean participant age (35 years) was
similar in both countries and over 96% lived with their partner.
Spanish participants were equally matched in terms of gender,
while in Italy the majority of respondents (79%) were female. In
Spain, 61.3% of respondents were expecting a child, while in
Table 1. Characteristics of participants who completed the final study
questionnaire.
Parameter
Spain
(N = 313)
Italy
(N = 302)
Personal data
Age in years, mean (range) 34.9
(20.0–67.0)
35.9
(19.0–62.0)
Gender, n (%)
Female 157 (50.2) 237 (78.5)
Male 156 (49.8) 65 (21.5)
Ethnicity, n (%)
Caucasian 300 (95.8) 289 (95.7)
Arabic/North African 8 (2.6) 3 (1.0)
African/African-American 1 (0.3) 2 (0.7)
Other 4 (1.3) 8 (2.6)
Education level, n (%)
Primary school 19 (6.1) 4 (1.3)
High school 81 (25.9) 153 (50.7)
Bachelor’s degree 59 (18.8) 48 (15.9)
University degree 96 (30.7) 65 (21.5)
Other 58 (18.5) 32 (10.6)
Living with a partner, n (%) 303 (96.8) 291 (96.4)
Already has children, n (%)
1 114 (36.4) 135 (44.7)
2 or more 61 (19.5) 135 (44.7)
Expecting child, n (%) 192 (61.3) 7 (2.3)
Pertussis experience
Personal or family member or social contacts with
prior infection, n (%)
27 (8.6) 97 (32.1)
Previous pertussis vaccination, n (%)
Yes 61 (19.5) 59 (19.5)
Yes, and within previous 10 years 3 (1.0) 14 (4.6)
Yes, but cannot recall when 28 (8.9) 30 (9.9)
No 102 (32.6) 135 (44.7)
Uncertain 150 (47.9) 108 (35.8)
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Italy only 2.3% were expectant. Most participants already had
children although the proportion was higher in Italy (89.4%)
than in Spain (55.9%). While education levels were broadly
comparable in either country, more Spanish respondents had
a University degree than Italian respondents (Table 1).
Most participants had no prior direct experience of pertussis
(either personal or within their family/social contacts), although
perception of pertussis was more frequent in Italy than in Spain
(32.1% and 8.6% respectively). In either country, less than 20%
of patients could recall any prior pertussis vaccination and most
that did so could not clearly recall when this was; the number
reporting vaccination anytime within the previous 10 years was
low; Spain (1.0%) and Italy (4.6%) (Table 1).
Questionnaire experience
The questionnaire was well understood by most respondents,
with 94.9% of Spanish respondents and 97.4% of Italian
respondents understanding all of the survey questions;
Spanish respondents took slightly longer in completion time
than in Italy (21.1 and 15.2 minutes respectively). An example
of a questionnaire choice is shown in Supplementary Figure 2.
Preferred scenarios for vaccine decision making
Participants built their preferred vaccination scenarios based
upon key attributes included in the questionnaire (Table 2).
Among the 144 scenarios fully available to the respondent,
infant protection by household vaccination at a vaccination
center, recommended by a family physician and health autho-
rities, with information available on leaflets and websites, was
the scenario most frequently selected (by 14% of the survey
sample in both countries) (Table 3). In both countries, vaccine
recommendation by both family physician and health autho-
rities was important, along with supportive information pro-
vided both by leaflets and websites. The proportion choosing
their partner and other children to be vaccinated in preferred
scenarios was lower in Italy than in Spain. Italian participants
favored immunization at vaccination centers, while many
Spanish respondents opted for vaccine administration by their
family physician or maternity unit.
Relative importance of attributes that influence vaccine
decision making
The relative importance of individual attributes varied
between countries. The attribute showing the highest relative
importance for Spanish respondents was the reduction in
source of infection (median, 23.1%; mean, 24.0%) with other
criteria of less importance (Figure 1 and Supplementary Table
1). In Italy, the differences in relative importance between
attributes were low, with median values mostly in the range
of 8.5–15%, with the highest importance assigned to vaccina-
tion location (median, 18.8%; mean 20.4%). In both countries,
the two attributes reflecting perception of media and social
contacts scored very low in relative importance (median
values, Spain, 3.1% and Italy, 3.5%).
When ranking the individual relative importance (cal-
culated for each participant), a slight majority of Spanish
respondents (50.2%) selected ‘vaccination(s) & source(s) of
infection’ as the most important attribute, while only 9.9%
of Italians did so (Supplementary Table 2). In contrast,
vaccine administration location (28.8%) and vaccine cost
(26.8%) were selected as having highest individual relative
importance by Italians. Overall, based on respondent’s
individual relative importance estimates, the number of
instances each attribute was selected as the most impor-
tant differed significantly between countries (Chi-squared
test, P < 0.01).
The number of instances each attribute was selected as one
of the three most important attributes, based on each respon-
dent’s relative importance, is shown in Supplementary Table 3.
Comparisons between specific respondent subgroups did not
show any significant association with participant gender (with
p-values of 0.08 and 0.21 for Spain and Italy respectively).
Similarly, no apparent associations between participants’ level
Table 2. Attributes and level of attributes used for the formal study questionnaire.
Attribute Levels
Vaccination(s) & source(s) of infection You only and could account for 39% of infections
You and your partner and could account for 55% of infections
You, your partner and your older child and could account for 84% of infections
Cost per person 25 euro
0 euro
Vaccination location At the pediatrician’s private practice
At the maternity unit, after delivery
At the vaccination center
At the family physician
Vaccine protection (years) 5
10
15
Recommended by Family physician
Pediatrician
Health Authorities
Family physician and the health authorities
Information You only receive the information orally
A printed leaflet is available for you to bring home
A printed leaflet and a website are available to ask questions online
TV, Newspaper, Radio Adverse
Favorable
Social network, Friends, Facebook, Twitter Adverse
Favorable
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of education or participant age (i.e., between those <35 years
and ≥35 years old) and attribute ranking were observed (data
not shown). The study, however, was not powered to demon-
strate specific differences in subgroups between or within
countries.
Preferences among each attribute
For each attribute, we analyzed the perceived value of the various
options proposed (with adjustment for multiple-comparisons
using the Bonferroni method). For most attributes, the choice
of lowest attribute preference and of attribute preference order
was identical in both countries (Figures 2 and 3 and
Supplementary Table 4). Exceptions were for ‘vaccination loca-
tion’, where ‘pediatrician’s private practice’was least preferred in
Spain and vaccination at the ‘maternity unit post-delivery’ was
least preferred in Italy, with minor changes to the ranking of
recommendation source. Ranking of ‘vaccination(s) & source(s)
of infection’ options showed a consistent preference for higher
level of reduction in source of infection, together with a higher
number of contacts being vaccinated. The availability of leaflets
and websites as sources of information was preferred in both
countries over traditional oral communication (which was least
preferred). Having both family physicians and health authority
entities recommending vaccination consistently favored vaccine
adoption. Among each attribute, the various options chosen
were statistically superior to the least preferred option used as
the reference, with the only exception being the ‘Health autho-
rities’ recommendation source in Italy (P = 0.05) with ‘Family
physician’ attribute as reference.
Vaccine adoption
The proportion of participants choosing probable or definite
vaccine adoption was high (Table 4 and Figure 4). When asked
about their subjective opinion on adoption under their preferred
(zero cost) vaccination scenario (as rated on a 5-point Likert-
scale), a majority of respondents in both Spain (90.4%) and Italy
(80.8%) indicated a definite or probable adoption response,
although a larger proportion of Spanish participants definitely
would adopt vaccination (63.7%) than in Italy (39.1%).
The estimated probability of vaccination adoption under their
preferred (zero cost) vaccination scenario was 97.7% for Spanish
respondents and 95.8% for Italian respondents (Supplementary
Table 3. Most ideal vaccination scenario selected by at least 3% of the Spanish and Italian participants.
Vaccination(s) & source(s) of
infection Cost Location
Duration of
protection
(years) Recommended by Information provided by Media
Social
network n %
Spain (N = 313)
You, your partner and your older
child and could account for
84% of infections
0€ Vaccination
center
15 Family physician and
health authorities
Printed leaflet and a website
to ask questions online
Favorable Favorable 46 14.7%
You, your partner and your older
child and could account for
84% of infections
0€ Family
physician
15 Family physician and
health authorities
Printed leaflet and a website
to ask questions online
Favorable Favorable 34 10.9%
You, your partner and your older
child and could account for
84% of infections
0€ Maternity
unit, post-
delivery
15 Family physician and
health authorities
Printed leaflet and a website
to ask questions online
Favorable Favorable 23 7.3%
You, your partner and your older
child and could account for
84% of infections
0€ Maternity
unit, post-
delivery
15 Pediatrician Printed leaflet Favorable Favorable 13 4.2%
You and your partner and could
account for 55% of infections
0€ Family
physician
15 Family physician and
health authorities
Printed leaflet and a website
to ask questions online
Favorable Favorable 12 3.8%
You, your partner and your older
child and could account for
84% of infections
0€ Family
physician
15 Family physician Printed leaflet and a website
to ask questions online
Favorable Favorable 12 3.8%
You, your partner and your older
child and could account for
84% of infections
0€ Maternity
unit, post-
delivery
15 Pediatrician Printed leaflet and a website
to ask questions online
Favorable Favorable 11 3.5%
You, your partner and your older
child and could account for
84% of infections
0€ Family
physician
15 Family physician and
health authorities
Printed leaflet Favorable Favorable 10 3.2%
Italy (N = 302)
You, your partner and your older
child and could account for
84% of infections
0€ Vaccination
center
15 Family physician and
health authorities
Printed leaflet, and a website
to ask questions online
Favorable Favorable 42 13.9%
You and your partner and could
account for 55% of infections
0€ Vaccination
center
15 Family physician and
health authorities
Printed leaflet and a website
to ask questions online
Favorable Favorable 12 4.0%
You only and could account for
39% of infections
0€ Vaccination
center
15 Family physician and
health authorities
Printed leaflet and a website
to ask questions online
Favorable Favorable 12 4.0%
You, your partner and your older
child and could account for
84% of infections
0€ Vaccination
center
15 Health authorities Printed leaflet and a website
to ask questions online
Favorable Favorable 11 3.6%
You and your partner and could
account for 55% of infections
0€ Vaccination
center
15 Pediatrician Printed leaflet and a website
to ask questions online
Favorable Favorable 11 3.6%
You and your partner and could
account for 55% of infections
0€ Vaccination
center
15 Health authorities Printed leaflet Favorable Favorable 10 3.3%
Respondents were asked to select their preferred option for each of the 4 attributes for which options were not offered logically (‘Vaccination and source(s) of
infection’; ‘Location’; ‘Recommended by’; and ‘Information provided by’. For other attributes, respondent choice was imputed based upon the best logical answer
(Cost, €0; Duration, 15 years; Media, favorable; Social network, favorable).
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Table 5). Vaccine costs had an impact on adoption.When vaccine
costs (25€ per person) were applied, the probability of uptake fell
by 7–10% in those participants initially choosing to definitely
adopt; from 97.7% to 91.0% in Spain and from 95.8% to 86.4%
in Italy. In those choosing to probably adopt, the probability of
uptake also fell (from 90.5% to 73.7% in Spain and from 89.3% to
69.4% in Italy). For those participants who were less certain, a 25€
vaccine cost lowered adoption rates by 11–30% (Supplementary
Table 5 and Supplementary Figure 3). These reductions in the
probability of uptake in the various Likert-scale categories are the
consequence of the preferences for zero cost vaccination
(Figure 4).
Discussion
Understanding key determinants of decision-making is an
important aspect of vaccine policy and implementation to
counteract vaccine hesitancy. While previous cross-sectional
questionnaire studies have evaluated parental personal and
psychosocial determinants of cocooning adoption,20,21 to our
knowledge this is the first study formally evaluating broader
aspects of pertussis cocooning using a conjoint approach.
An adaptive approach to DCE is an established method in
evaluating healthcare choices,33-36 and comparisons between
adaptive and more standard DCE approaches show compar-
able results,37-39 with the adaptive approach allowing screen-
ing of a larger number of attributes and levels with a lower
number of subjects. ADCE also limits some bias.40 An adap-
tive implementation (i.e., ADCE) was considered to provide
a better fit to the aims of our surveys than a DCE approach;
mainly due to the greater amount of individualized data
collected and the lower variance offered by the ADCE
approach compared with that obtained from a static DCE
approach. Attribute levels were selected based upon vaccina-
tion and implementation policy, with data for the relative
proportion of infant infection due to specific types of house-
hold contacts based on that reported by Wiley et al.41
Our survey indicates that the uptake of pertussis vaccina-
tion to provide indirect protection to their newborn infant in
a cocooning strategy was positively received by mothers and
fathers in both Spain and Italy, with 89–98% indicating
a definite or probable adoption response. This is consistent
with previous studies exploring attitudes to cocooning, with
surveys conducted in Dutch and Australian populations
Figure 1. Relative importance of attributes.
The distribution of the individual relative importance across subjects is presented for each attribute, separately for each country. The individual estimates of the
relative importance are derived from the Bayesian estimations of the part-worth utilities using a hierarchical multinomial logit model.
The limits of the boxes represent the 1st and 3rd quantiles and the bars in the middle represent the medians. The symbols within the boxes represent the means.
The whiskers around the boxes extend up to 1.5 times the interquartile ranges. All extreme observations are shown using symbols beyond the whiskers.
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reporting positive intention rates of 78% and 96%
respectively.20,21 The respondents’ most frequent preferred
scenario was one that offered the greatest protection; vaccina-
tion of all household contacts (i.e., themselves, their partner
and older children), an aspect also supported by Dutch and
Australian studies, where risk perception (of pertussis disease
and transmission to infant) and expected efficacy of the per-
tussis vaccination were key themes in forming a positive
opinion to cocooning, with such perceived vaccine benefits
being an independent predictor of vaccine uptake.19,21,22
Vaccination habit seems to have an important influence on
respondent preferences. In Italy, greater preferences seem to
be given to vaccination centers, which are well established in
delivering disease-prevention measures for all ages. However,
in Spain, vaccination settings are different: children receive
vaccinations in primary care centers by a pediatric nurse
assigned to the child, whereas adults are administered vacci-
nations by a public health nurse assigned to the adult. Due to
these organizational differences between Spain and Italy, the
importance of preference location and specific location of
delivery was more variable between the two countries.
The majority of our survey respondents in both countries
had limited perception or experience of pertussis and vac-
cine recommendations by both their family physician and
the health authorities were important factors in their deci-
sion-making, along with information about benefits (both
printed information and that available on a website). In
comparison, the value of other media information or that
from social contacts were considered less important. The
value and source of professional recommendations in influ-
encing adoption of vaccination in general and of pertussis
cocooning in particular has been reported in a number of
studies,14,18-20,26,42-45 In China, vaccination promotions have
been shown as influencing parent attitudes toward children
vaccination44 and, in sub-Saharan Africa, access to informa-
tion has been highlighted as being a key determinant in
reducing the rates of missed opportunities for children
immunization.45 In Australia, one study found that willing-
ness to receive pertussis vaccination post-partum was 7-fold
greater in women who had received a recommendation
compared to those without any such information,43 and
a second Australian study found that acceptance was 1.7
times more likely following a recommendation.19 Studies
performed elsewhere e.g., in the United States, report even
greater influences of professional recommendations on
adoption of pertussis cocooning.46
We found some differences in the relative importance of
attributes in either country (e.g., reduction in infection risk
was more important to Spanish respondents, whereas location
of vaccine delivery was more important to Italian respon-
dents). Notably, gender did not appear to influence the rela-
tive importance of these determinants on vaccination choices.
Cocooning prevention is less cost effective than maternal
immunization, as a high reduction in the numbers of sources of
Figure 2. Relative utilities and utility differences in Spain.
Mean part-worth utilities are presented using a colored line connecting all levels for the same attribute. Bonferroni-adjusted p-values for the difference compared to
the utility of the lowest level are presented close to each point.
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infection requires vaccinating all household contacts and poten-
tially other newborn-contacts.47 As such, cocooning should be
considered when maternal ante-partum vaccination should be
avoided or when it is not the mother’s personal preference.
Data on the impact of vaccine cost on the adoption of
a cocooning strategy by close contacts is limited. In our
survey, we found that including a vaccine cost (of 25€ per
person) had a relatively minor effect on the probability of
vaccine adoption in the most convinced ‘Definitely will buy’
respondents (63.7% and 39.1% of Spanish and Italian respon-
dents respectively). In those subjects that answered ‘Probably
will buy’ a reduction in the mean probability of 16–20% was
observed in that group. Vaccination cost is therefore an
important factor in vaccine adoption, especially in those that
have some hesitations or doubts; 26.7% and 41.8% of all
respondents in Spain and Italy respectively.
In Italy, the tetanus-diphtheria-acellular pertussis decennial
booster vaccine (Tdap) for adults and elderly is now included
free of charge as part of the National Immunization Program. In
view of our survey results, an increase of Tdap acceptance by
a broader group of eligible adults could be realized in Italy,
provided that other important determinants (i.e., place of vac-
cination, recommendation by physicians and authorities, etc.)
are fulfilled. In contrast, in Spain, Tdap is provided at no cost
only to pregnant women and healthcare workers, and so uptake
by other adult close contacts may be influenced by cost.
Our study has some limitations. Participant recruitment
makes the survey results vulnerable to selection bias. Our
survey was not designed to be representative of the Spanish
or Italian populations and reflects opinions of a random sam-
ple of subjects visiting the investigating centers (and subjects
who were not a-priori against vaccination as a prevention
measure). Our principal aim was to evaluate vaccine prefer-
ences qualitatively within each country, and pooled across
both countries if no substantial differences between Spain
and Italy were found. The statistically significant differences
we found between countries did not allow us to do so. While
we have reported some of these differences in preferences,
these should be considered in the context of a relatively small
sample size in a non-randomized cohort.
Some demographic differences between Spain and Italy may
have influenced the differences we observed in attribute rank-
ing (and indeed differences between centers within each coun-
try). For example, the majority of Italian participants already
had newborn contact and so we were unable to evaluate the
choices of expectant newborn contacts in Italy, and indeed
some attribute levels (e.g., vaccination at the maternity unit)
were therefore irrelevant and hence given a lower preference
score. As described above, differences in vaccine services and
delivery locations may also influence differences between coun-
tries. In addition, we did not formally evaluate differences
based on the relationship of the respondent (i.e., mother,
father, or another adult household contact) to the newborn or
expected newborn. Other demographic variations (including
respondent education level, income and nature of recruitment
center) could also have influenced our results, as our study
Figure 3. Relative utilities and utility differences in Italy.
Mean part-worth utilities are presented using a colored line connecting all levels for the same attribute. Bonferroni-adjusted p-values for the difference compared to
the utility of the lowest level are presented close to each point.
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design and sample size did not allow stratification of results for
specific analysis of these aspects.
Finally, although a high level of internal consistency was
seen during scoping and survey development, the question-
naire was not formally externally validated according to
a formal vaccine buying and administration process.
Nevertheless, our survey identifies key aspects that influ-
ence cocooning acceptance by parents and close contacts of
Spanish and Italian newborns, and demonstrates a high rate of
positive intention of pertussis vaccine uptake.
Figure 5 summarizes the context, outcomes, and impact of
this survey for HCPs. Our survey was intended to explore
factors influencing vaccine uptake and vaccine hesitancy to
better understand how to improve patient communication.
Our survey suggests that vaccine adoption would be wel-
comed by those Italian and Spanish parents who do not
harbor inherent objections to vaccination. Appreciating the
attributes described in this survey that influence vaccine
uptake may assist communicating future pertussis vaccination
strategies as necessary. This information may be helpful in
assisting HCPs in Spain and Italy to engage with their appro-
priate vaccine target populations.
Methods
Study design and study population
This was a cross-sectional questionnaire study (NCT01890447)
conducted between January 2015 and February 2016 in 313
adults from five centers in Spain (Barcelona, Getafe/Madrid,
Leioa, Pamplona, and Parla) and in 302 adults from four
centers in Italy (San Severo, Chiavari, Ragusa, and Cuneo).
Figure 4. Probability of vaccine adoption.
Figure 4(a) represents the respondent probability of vaccine adoption using logistic regression calibrated through a series of six vaccination scenarios.
Figure 4(b) represents the proportion of respondents choosing possible likelihood of adoption level preferences. Probability of adoption is calculated considering the
most ideal vaccination scenario for each subject assuming vaccination at zero cost (solid curve) and at a cost of 25€ per person (dashed curve) presented for both
Spain and Italy. Probabilities are based upon the subjective opinions of the respondents on their likelihood of adoption under their ideal vaccination scenario. The
‘Definitely will not buy’ category included in Supplementary Table 5 is not presented graphically as the number of subjects contributing to that category was not
sufficient to provide reliable estimates.
Table 4. Participant’s subjective opinions on vaccine adoption under their most preferred scenario.
Countrya
Definitely will not buy Probably will not buy Might or might not buy Probably will buy Definitely will buy
n % n % n % n % n %
Spain (N = 311) 5 1.6% 4 1.3% 21 6.8% 83 26.7% 198 63.7%
Italy (N = 297) 3 1.0% 10 3.4% 44 14.8% 124 41.8% 116 39.1%
Respondents were presented scenarios based upon their previous survey responses, as included in their preferred scenarios. Data presented corresponds to the
likelihood of vaccination adoption for that scenario. A Likert-scale was used to capture respondents’ readiness to ‘buy’ (i.e., adopt) the proposed vaccination option.
aSome subjects did not complete this section of the survey (Spain, n = 2; Italy, n = 5).
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Participants were households or other close contacts of new-
borns aged ≤6 months of age (or expectant mothers in their last
trimester or their partners), recruited from those receiving
routine pre- or post-natal obstetric care. All participants had
to be ≥18 years of age, capable of understanding the question-
naire, and had to be eligible to receive pertussis booster vacci-
nation (with no history of pertussis vaccination in the previous
2 years). Individuals not fulfilling these criteria or those with
self-declared objections to vaccination, those with a history of
pertussis in the last 5 years before the start of the study, and
those with unstable chronic health condition(s) were ineligible.
No financial incentives were offered.
Study questionnaire development
The study was performed in two stages; an initial pilot ques-
tionnaire design phase followed by a formal enrolment study
phase. Before the pilot phase, draft questionnaire development
was facilitated by a focus group approach.48 Three investigator-
led focus groups (drawn fromHCPs and parent representatives)
were formed in each country (between September-December
2013) and a range of potential attributes to be considered for
inclusion in the questionnaire were discussed, along with how to
present attribute choices. All feedback was collated and centra-
lized. The key attributes were identified and their level of impor-
tance formed the basis of a draft questionnaire, which included
1) an explanation of pertussis infection and the rationale for
cocooning; 2) study objectives; and 3) a sequence of questions
regarding reasons/attributes that influence vaccination choice
and levels of importance. In general, the results from Spanish
and Italian focus groups were consistent.
Both the pilot draft questionnaire and the final formal
survey questionnaire were designed and implemented using
the Sawtooth Software SSI-Web version 8.4.8 (Sawtooth
Software; SSI Web, Orem, Utah, United States). Identical
questionnaires were administered in both countries; question-
naires were initially developed in English and then translated
into Spanish and Italian language versions.
In the pilot phase, approximately 50 participants from each
country were randomized (computer generated 1:1 ratio) to
complete either the DCE or ADCE questionnaire (conducted
between September 2014 and January 2015). Based on the
pilot phase, an ADCE format was considered more suitable
for the formal survey; in particular, as some subjects consid-
ered some attributes as unacceptable (suggesting non-
compensatory behavior) we preferred to use a methodology
that accounted specifically for such behavior. In addition,
these attribute levels were further defined and updated with
the final questionnaire showing near-complete orthogonality
(i.e., minimal correlation between attributes).
Final questionnaire
Demographic data (age, gender, education status, number of
children, contacts at home, and pertussis vaccination history)
were collected from each respondent completing the final
questionnaire (between January 2015 and February 2016).
The definitive questionnaire comprised questions on eight
attributes; source of infection and likelihood of infection to
the newborn; duration of vaccine protection; vaccine cost;
vaccination location (primary care physician’s office, pediatri-
cian’s office, vaccination center/clinic, in maternity unit fol-
lowing delivery); source of vaccination recommendation (i.e.,
pediatrician, primary care physician and/or health authority);
source of supporting information (oral, printed leaflet and/or
internet-based); and opinions expressed in traditional (news-
papers, television/radio) and social media or by acquain-
tances. Each attribute was described in terms of distinct
scenarios so generating a number of choice sets with two or
more hypothetical options.
Figure 5. Focus on the patient section.
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Sample size and data analysis
Determining sample size in conjoint analyses is challenging,49 as
this depends on the proportion of respondents choosing each
attribute scenario. As this was unknown to us prior to enrol-
ment, we adopted an incidence precision approach50 fromwhich
we anticipated that, for a minimum number of 8 choice sets per
participant, a minimum of 200 individuals from each country
was required to achieve 10% precision at a 95% confidence level.
The sample size was increased to 250 to account for any non-
minimal-variance in questionnaire design. In actuality, over 300
participants from each country were recruited.
All data was anonymized and the statistical analyzes were
performed using the Sawtooth Software SSI-Web version 8.4.8
and SAS (version 9.4M2 on Windows). Data on participant
demographics and attribute relative importance are presented
in descriptive terms. The relative importance of attributes indi-
cates the impact of that attribute in participant decision-
making in choosing a vaccination scenario, relative to all
other attributes. Utility values (‘part-worth’ values) for each
attribute were calculated using the part-worth utilities of the
multinomial logit model and hierarchical Bayesian analysis
implemented by the Sawtooth Software. Utility differences
were calculated between the most and the least preferred
options for each attribute, with the relative importance based
on the extent of these utility differences. The relative impor-
tance for each attribute was calculated for each participant,
leveraging hierarchical Bayesian analysis. Ranking of impor-
tance across attributes was based on the average relative impor-
tance values across the whole respondent population and the
proportion of participants rating that attribute as having the
highest relative importance. For preferences among specific
attributes, the differences between the mean (‘part-worth’) uti-
lities were calculated, using the lowest utility as a reference,
with approximate p-values calculated after adjustment for mul-
tiple-comparisons by the Bonferroni method.
The impact of vaccine costs on the probability of vaccine
adoption was calculated using relative utilities; the utility thresh-
old above which the respondent would adopt vaccination was
calibrated through a series of six vaccination scenarios and the
stated (subjective) likelihood of adoption for each scenario. The
utility threshold above which an adoption would occur was based
on a regression approach. Likelihood of adoption was elicited
using categories of subjective participant opinions; definitely/
probably will not buy, might ormight not buy, probably/definitely
will buy, and utilities for which the subjective opinion was super-
ior to ‘might or might not buy’ were considered to lead to adop-
tion. A logistic regression curve was calibrated on these data, using
a 50% probability of vaccination adoption at the approximate
mid-point between ‘Might or might not buy’ and ‘Probably will
buy’ levels of the Likert-scale used to capture each respondent’s
answer. Probabilities of vaccine adoption were calculated for each
participant’s most preferred scenario (zero cost) and compared to
probabilities when a 25€ per person cost was applied.
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